De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

AIM Vaccine Beheer

Beheer criteriumcontroles 3/4

De CEO AIM Vaccine's is Yan Zhou, benoemd in Sep2020, heeft een ambtstermijn van 4.08 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 2.18M, bestaande uit 86.5% salaris en 13.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 16.62% van de aandelen van het bedrijf, ter waarde HK$ 1.80B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 4.2 jaar.

Belangrijke informatie

Yan Zhou

Algemeen directeur

CN¥2.2m

Totale compensatie

Percentage CEO-salaris	86.5%
Dienstverband CEO	4.1yrs
Eigendom CEO	16.6%
Management gemiddelde ambtstermijn	3.5yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Yan Zhou's beloning veranderd ten opzichte van AIM Vaccine's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CN¥1b
Mar 31 2024	n/a	n/a	-CN¥1b
Dec 31 2023	CN¥2m	CN¥2m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥913m
Jun 30 2023	n/a	n/a	-CN¥525m
Mar 31 2023	n/a	n/a	-CN¥422m
Dec 31 2022	CN¥2m	CN¥2m	-CN¥320m
Dec 31 2021	CN¥899m	CN¥1m	-CN¥693m

Compensatie versus markt: De totale vergoeding ($USD 309.89K ) Yan } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 564.92K ).

Compensatie versus inkomsten: De vergoeding van Yan is gestegen terwijl het bedrijf verliesgevend is.

CEO

Yan Zhou (57 yo)

4.1yrs

Tenure

CN¥2,175,000

Compensatie

Mr. Yan Zhou is Executive Chairman and Chief Executive Officer of AIM Vaccine Co., Ltd. September 2020. He has served as a Director of AIM Vaccine Co., Ltd.since May 2015 and was re-designated as an execu...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yan Zhou	Executive Chairman & CEO	4.1yrs	CN¥2.18m	16.62% HK$ 1.4b
Xin Zhou	Executive Vice-Chairman & Executive President	11.4yrs	geen gegevens	3.3% HK$ 280.0m
Wen Guan	Vice-Chairman of the Board & Executive President	3.7yrs	CN¥2.23m	geen gegevens
Jie Zhou	Executive Director & Executive President	less than a year	geen gegevens	3.3% HK$ 280.0m
Shaojun Jia	COO, Executive President & Executive Director	3.7yrs	CN¥2.43m	0.84% HK$ 71.1m
Lixin Niu	Chief Financial Officer	9yrs	geen gegevens	geen gegevens
Ling Liu	Secretary & Chief Investment Officer	8.9yrs	geen gegevens	geen gegevens
Zhang Fan	Chief Research Officer	3.6yrs	geen gegevens	geen gegevens
Meng Li	Chief Quality Officer	2.5yrs	geen gegevens	geen gegevens
Zhou Wenjuan	Chief Public Affairs Officer	2.6yrs	geen gegevens	geen gegevens
Lin Zhenyu	Chief Marketing Officer	2.6yrs	geen gegevens	geen gegevens
Wing Chi Lam	Joint Company Secretary	3.3yrs	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 6660 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yan Zhou	Executive Chairman & CEO	9.4yrs	CN¥2.18m	16.62% HK$ 1.4b
Xin Zhou	Executive Vice-Chairman & Executive President	11.4yrs	geen gegevens	3.3% HK$ 280.0m
Wen Guan	Vice-Chairman of the Board & Executive President	3.7yrs	CN¥2.23m	geen gegevens
Jie Zhou	Executive Director & Executive President	9.4yrs	geen gegevens	3.3% HK$ 280.0m
Shaojun Jia	COO, Executive President & Executive Director	7.2yrs	CN¥2.43m	0.84% HK$ 71.1m
Ker Wei Pei	Independent Non-Executive Director	4.1yrs	CN¥300.00k	geen gegevens
Tingfeng Song	Chairman of The Supervisory Committee	3.7yrs	geen gegevens	geen gegevens
Hui Ouyang	Independent Non-Executive Director	3.4yrs	CN¥300.00k	geen gegevens
Aijun Wang	Non-Executive Director	7.1yrs	geen gegevens	4.13% HK$ 350.0m
Xiaoguang Guo	Independent Non-Executive Director	3.7yrs	CN¥300.00k	geen gegevens
Jichen Zhao	Non-Executive Director	4.3yrs	geen gegevens	geen gegevens
Jie Wen	Independent Non-Executive Director	3.4yrs	CN¥300.00k	geen gegevens

4.2yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6660 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

AIM Vaccine Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

AIM Vaccine Co., Ltd. Announces Re-Designation of Directors

AIM Vaccine Co., Ltd., Annual General Meeting, May 20, 2024

AIM Vaccine Co., Ltd. Announces Executive Changes

AIM Vaccine Co., Ltd. Announces Board Appointments

Executive Chairman & CEO recently bought HK$249k worth of stock

Executive Chairman & CEO recently bought HK$716k worth of stock

Recent updates

AIM Vaccine Co., Ltd. Announces Unblinding of Data from Phase III Clinical Trial of Iterative Serum-Free Rabies Vaccine

New minor risk - Share price stability

First half 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.21 loss in 1H 2023)

AIM Vaccine Co., Ltd. Announces Submission of Official Application for Clinical Trials for Absorbed Tetanus Vaccine

AIM Vaccine Co., Ltd. Announces Re-Designation of Directors

AIM Vaccine Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Aim Vaccine Co., Ltd. Announces Submission of Pre-Applications for Clinical Trials for Two mRNA Vaccines of Respiratory Syncytial Virus (RSV) And Shingles/Herpes Zoster of Aim Vaccine

AIM Vaccine Co., Ltd., Annual General Meeting, May 20, 2024

Full year 2023 earnings released: CN¥1.07 loss per share (vs CN¥0.27 loss in FY 2022)

AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for quadrivalent influenza virus vaccine (MDCK Cells)

AIM Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Novel-Process Highly-Effective Human Diploid Rabies Vaccine

New minor risk - Financial data availability

AIM Vaccine Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

AIM Vaccine Co., Ltd. Announces Completion of Application for Marketing of 13-Valent Pneumonia Conjugate Vaccine, Iterative Serum-Free Rabies Vaccine and 23-Valent Pneumonia Polysaccharide Vaccine

AIM Vaccine Co., Ltd. Submits the Pre- Application for Marketing Registration for Its 13-Valent Pneumonia Conjugate Vaccine

AIM Vaccine Co., Ltd. Announces Executive Changes

AIM Vaccine Co., Ltd. Announces Board Appointments

Executive Chairman & CEO recently bought HK$249k worth of stock

Executive Chairman & CEO recently bought HK$716k worth of stock

Executive Chairman & CEO recently bought HK$525k worth of stock

Executive Chairman & CEO recently bought HK$1.3m worth of stock

Aim Vaccine Co., Ltd. Announces Phase III Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine Is Near Completion and Statistical Unblinding Will Commence Soon

AIM Vaccine Co., Ltd. Announces Completion of Full Course of Vaccination in Subjects of Phase III Clinical Trial of 23-Valent Pneumococcal Polysaccharide Vaccine

New minor risk - Share price stability

Aim Vaccine Co., Ltd. Announces Phase III Clinical Trial of Serum-Free Rabies Vaccine Acciedated Satisfactory Phase Results

First half 2023 earnings released

AIM Vaccine Co., Ltd. Announces Initiation of Randomized, Blinded and Compatible Vaccine-Controlled Phase III Clinical Trial of 23-Valent Pneumococcal Polysaccharide Vaccine

AIM Vaccine Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

AIM Vaccine Co., Ltd. Announces Bivalent mRNA Vaccine Against COVID-19 Variants Delta and OmicronBA.5 Obtains Clinical Trial Approval from National Medical Products Administration of China

AIM Vaccine Co., Ltd. Announces PRC National Medical Products Administration Accepts Application for Clinical Trial of Human Rabies mRNA Vaccine Against Rabies Virus

AIM Vaccine Co., Ltd. Announces Major Results of a Study on Protective Efficacy of COVID-19 Variant Omicron BA.5 mRNA Vaccine LVRNA012

Full year 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.60 loss in FY 2021)

Less than half of directors are independent

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd